With New CEO in Place, Orchid Moves to Trim GeneShield; Additional Restructuring Possible | GenomeWeb

We're not out of the woods yet,” Orchid Biosciences CFO Andrew Savadelis said in early March. “But we see the light shining through the trees.”

The woods must be deeper than he’d estimated.

Three months after putting its diagnostics unit on the block — and one day before new chief executive Paul Kelly was to take the helm — Orchid announced May 30 that it had restructured its GeneShield personalized medicine business unit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.